Catalyst Pharmaceuticals (NASDAQ:CPRX) issued its earnings results on Monday. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.02), Morningstar.com reports.
Shares of CPRX opened at $3.08 on Tuesday. Catalyst Pharmaceuticals has a 1 year low of $1.85 and a 1 year high of $4.05.
Several analysts have issued reports on the company. BidaskClub raised Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, February 25th. Zacks Investment Research lowered Catalyst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, February 13th. HC Wainwright reaffirmed a “buy” rating on shares of Catalyst Pharmaceuticals in a research note on Friday, December 14th. Cantor Fitzgerald set a $9.00 target price on Catalyst Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, December 13th. Finally, Piper Jaffray Companies upped their target price on Catalyst Pharmaceuticals from $5.00 to $7.50 and gave the stock an “overweight” rating in a research note on Thursday, December 13th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $6.35.
In related news, Director Donald A. Denkhaus acquired 25,000 shares of the company’s stock in a transaction dated Thursday, December 27th. The stock was purchased at an average price of $1.91 per share, with a total value of $47,750.00. Following the completion of the purchase, the director now owns 225,000 shares in the company, valued at approximately $429,750. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Patrick J. Mcenany acquired 20,000 shares of the company’s stock in a transaction dated Wednesday, December 19th. The shares were bought at an average cost of $2.24 per share, with a total value of $44,800.00. Following the purchase, the insider now owns 4,737,693 shares of the company’s stock, valued at approximately $10,612,432.32. The disclosure for this purchase can be found here. 9.30% of the stock is owned by corporate insiders.
Several large investors have recently added to or reduced their stakes in CPRX. Broadfin Capital LLC boosted its stake in shares of Catalyst Pharmaceuticals by 22.0% during the fourth quarter. Broadfin Capital LLC now owns 6,268,298 shares of the biopharmaceutical company’s stock valued at $12,035,000 after purchasing an additional 1,132,034 shares during the period. BlackRock Inc. boosted its stake in shares of Catalyst Pharmaceuticals by 11.5% during the fourth quarter. BlackRock Inc. now owns 6,970,873 shares of the biopharmaceutical company’s stock valued at $13,384,000 after purchasing an additional 719,093 shares during the period. Panagora Asset Management Inc. boosted its stake in shares of Catalyst Pharmaceuticals by 120.2% during the third quarter. Panagora Asset Management Inc. now owns 611,450 shares of the biopharmaceutical company’s stock valued at $2,311,000 after purchasing an additional 333,821 shares during the period. Dimensional Fund Advisors LP purchased a new stake in shares of Catalyst Pharmaceuticals during the third quarter valued at approximately $990,000. Finally, Vanguard Group Inc boosted its stake in shares of Catalyst Pharmaceuticals by 4.3% during the third quarter. Vanguard Group Inc now owns 4,458,151 shares of the biopharmaceutical company’s stock valued at $16,852,000 after purchasing an additional 185,017 shares during the period. 47.83% of the stock is owned by hedge funds and other institutional investors.
WARNING: This piece of content was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2019/03/19/catalyst-pharmaceuticals-cprx-announces-quarterly-earnings-results.html.
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3.
Featured Story: What is Depreciation?
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.